

CLAIMS

1. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound represented by the formula:




or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound represented by the formula:




or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound represented by the formula:



or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition for use in treating or preventing a viral infection in a patient, wherein the composition comprises a pharmaceutically effective amount of a compound represented by the formula:



or a pharmaceutically acceptable salt thereof.

5. The pharmaceutical composition for use according to claim 4, wherein the viral infection is caused by a human coronavirus, Eastern equine encephalitis virus, Western equine encephalitis


virus, Venezuelan equine encephalitis virus, Chikungunya virus, Ross River virus, RSV virus, influenza A virus, influenza B virus, or Ebola virus infection.

6. The pharmaceutical composition for use according to claim 4 or claim 5, wherein the viral infection is caused by a human coronavirus.

7. The pharmaceutical composition for use according to any of claims 4 - 6, wherein the viral infection is caused by a SARS coronavirus or MERS coronavirus.

8. The pharmaceutical composition for use according to any of claims 4 - 7, wherein the viral infection is caused by a SARS coronavirus.

9. A pharmaceutical composition for use in treating or preventing a viral infection, wherein the composition comprises a pharmaceutically effective amount of a compound represented by the formula:



or a pharmaceutically acceptable salt thereof.


10. The pharmaceutical composition for use according to claim 9, wherein the viral infection is caused by a human coronavirus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, Chikungunya virus, Ross River virus, RSV virus, influenza A virus, influenza B virus, or Ebola virus infection.

11. The pharmaceutical composition for use according to claim 9 or claim 10, wherein the viral infection is caused by a human coronavirus

12. The pharmaceutical composition for use according to any of claims 9 - 11, wherein the viral infection is caused by a SARS coronavirus or MERS coronavirus.

13. The pharmaceutical composition for use according to any of claims 9 - 12, wherein the viral infection is caused by a SARS coronavirus.

14. A compound represented by the formula:



or a pharmaceutically acceptable salt thereof for use in treating or preventing a viral infection in a patient.


15. The compound for use according to claim 14, wherein the viral infection is caused by a human coronavirus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, Chikungunya virus, Ross River virus, RSV virus, influenza A virus, influenza B virus, or Ebola virus infection.

16. The compound for use according to claim 14 or claim 15, wherein the viral infection is caused by a human coronavirus.

17. The compound for use according to any of claims 14 - 16, wherein the viral infection is caused by a SARS coronavirus or MERS coronavirus.

18. The compound for use according to any of claims 14 - 17, wherein the viral infection is caused by a SARS coronavirus.


19. A compound represented by the formula:



or a pharmaceutically acceptable salt thereof for use in treating or preventing a viral infection in a patient.


20. The compound for use according to claim 19, wherein the patient is a human.

21. A compound represented by the formula:




or a pharmaceutically acceptable salt thereof.

22. A compound represented by the formula:




or a pharmaceutically acceptable salt thereof.

23. The compound of claim 21, represented by the formula:




.

24. The compound of claim 21, wherein the compound is a pharmaceutically acceptable salt of



.

25. A compound represented by the formula:



or a pharmaceutically acceptable salt thereof for use in the treatment of a human coronavirus, Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, Chikungunya virus, Ross River virus, RSV virus, influenza A virus, influenza B virus, or Ebola virus infection.


26. The compound for use according to claim 25, wherein the viral infection is caused by a human coronavirus

27. The compound for use according to claim 25 or claim 26, wherein the viral infection is caused by a SARS coronavirus or MERS coronavirus.

28. The compound for use according to any of claims 25 - 27, wherein the viral infection is caused by a SARS coronavirus.


29. The compound for use according to any one of claims 25 - 28, wherein the patient in need thereof is human.

30. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a pharmaceutically acceptable salt of a compound represented by the formula:




.

31. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound represented by the formula:



.


32. A compound represented by the formula:



or a pharmaceutically acceptable salt thereof for use in the treatment of a human coronavirus infection in a patient in need thereof.

33. The compound for use according to claim 32, wherein the patient in need thereof is human.

34. A compound represented by the formula:



for use in the treatment of a human coronavirus infection in a patient in need thereof.

35. The compound for use according to claim 34, wherein the patient in need thereof is human.